FGEN
FibroGen Inc
Halal Rating :
Last Price
$0.59
Last updated:
Market Cap
-
7D Change
0.2%
1 Year Change
-32.83%
Company Overview
Industries
Exchange
Next Earnings Date
FibroGen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company's primary focus is on developing medicines for anemia, fibrotic disease, and cancer. Their lead product, roxadustat, is approved in China for the treatment of anemia in chronic kidney disease (CKD) patients.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $46.33m | $68.11m | - | $4.99m | 0.00% | 7.33% |
| June 30, 2024 | $50.64m | $66.34m | - | $4.78m | 0.00% | 7.21% |
| March 31, 2024 | $55.9m | $91.96m | - | $5.0m | 0.00% | 5.43% |
Company Impact
Help us evaluate FibroGen Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.